PLATINUM-RESISTANT RECURRENT OVARIAN CANCER
Clinical trials for PLATINUM-RESISTANT RECURRENT OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new PLATINUM-RESISTANT RECURRENT OVARIAN CANCER trials appear
Sign up with your email to follow new studies for PLATINUM-RESISTANT RECURRENT OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat ovarian cancer: experimental combo enters phase 2 trial
Disease control Recruiting nowThis study tests whether adding the experimental drug B013 to standard chemotherapy (paclitaxel) can help people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatments. About 90 participants will receive either the comb…
Matched conditions: PLATINUM-RESISTANT RECURRENT OVARIAN CANCER
Phase: PHASE2 • Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for hard-to-treat ovarian cancer: combo therapy enters human trial
Disease control Recruiting nowThis study tests a new drug called CapsuleX combined with cisplatin in 40 people whose ovarian cancer no longer responds to platinum-based chemotherapy. The goal is to see if the combination can shrink tumors and how safe it is. Participants must have confirmed ovarian, fallopian…
Matched conditions: PLATINUM-RESISTANT RECURRENT OVARIAN CANCER
Phase: NA • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC